MedTrace Logo

Mepivacaine-Tramadol on the Success of Inferior Alveolar Nerve Block in Symptomatic Irreversible Pulpitis

NCT02110966 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 56

Last updated 2014-10-31

No results posted yet for this study

Summary

The purpose of this study is to evaluate the success of inferior alveolar nerve block, after the local application of Mepivacaine plus Tramadol in patients with symptomatic irreversible pulpitis. Also, to evaluate the duration of the anesthetic effect when using Mepivacaine plus Tramadol in the same anesthetic technique and patients group.

Hypothesis:

Local application of mepivacaine plus tramadol increases the successful of inferior alveolar nerve block in patients with irreversible pulpitis.

Conditions

  • Symptomatic Irreversible Pulpitis

Interventions

DRUG

Mepivacaine

Drug: Tramadol 1.8 ml of Mepivacaine 2% epinephrine 1:100000.

DRUG

Mepivacaine plus Tramadol

0.5 ml of Tramadol mixed with 1.3 ml of Mepivacaine.

Sponsors & Collaborators

  • Daniel Chavarría Bolaños

    lead OTHER

Principal Investigators

  • Laura Rodríguez, DDS · Universidad Autónoma San Luis Potosí

  • Daniel Chavarria, MSc, PhD · Universidad Autonoma San Luis Potosi

  • Amaury Pozos, MSc, PhD · Universidad Autonoma San Luis Potosi

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2014-04-30
Primary Completion
2014-10-31
Completion
2014-10-31

Countries

  • Mexico

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02110966 on ClinicalTrials.gov